Cumberland Pharmaceuticals Inc. (CPIX) To Go Ex-Dividend on July 23rd

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced a dividend on Monday, July 13th. Investors of record on Thursday, July 23rd will be paid a dividend of 1.50 per share by the specialty pharmaceutical company on Friday, July 31st. The ex-dividend date is Thursday, July 23rd.

Cumberland Pharmaceuticals Stock Performance

Shares of CPIX stock opened at $6.99 on Wednesday. The stock’s 50-day moving average is $5.75 and its two-hundred day moving average is $4.47. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95. Cumberland Pharmaceuticals has a 1 year low of $1.85 and a 1 year high of $7.36. The firm has a market cap of $104.71 million, a price-to-earnings ratio of -14.27 and a beta of 0.09.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The firm had revenue of $9.13 million during the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Analyst Ratings Changes

CPIX has been the subject of several research reports. Wall Street Zen downgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.